CY1121781T1 - Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων - Google Patents

Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων

Info

Publication number
CY1121781T1
CY1121781T1 CY20191100699T CY191100699T CY1121781T1 CY 1121781 T1 CY1121781 T1 CY 1121781T1 CY 20191100699 T CY20191100699 T CY 20191100699T CY 191100699 T CY191100699 T CY 191100699T CY 1121781 T1 CY1121781 T1 CY 1121781T1
Authority
CY
Cyprus
Prior art keywords
rasagilline
extended
release pharmaceutical
pharmaceutical form
pharmaceutically acceptable
Prior art date
Application number
CY20191100699T
Other languages
English (en)
Inventor
Yoram Sela
Nurit Livnah
Itschak Lamensdorf
Tomer Madmon
Original Assignee
Pharma Two B Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121781(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd. filed Critical Pharma Two B Ltd.
Publication of CY1121781T1 publication Critical patent/CY1121781T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει διάφορες φαρμακευτικές συνθέσεις, συγκεκριμένα για από του στόματος χορήγηση, συνταγοποιημένες για παρατεταμένη απελευθέρωση δραστικών ενώσεων, χρήσιμων στην θεραπεία νευροεκφυλιστικών ασθενειών, συγκεκριμένα της νόσου Parkinson και βλαβών του νευρικού συστήματος. Η δραστική ένωση που συμπεριλαμβάνεται εντός αυτών των συνθέσεων κατά προτίμηση επιλέγεται από Ν-προπαργυλ-1-αμινοϊνδάνιο, εναντιομερές αυτού ή φαρμακευτικώς αποδεκτό άλας αυτού, περισσότερο προτιμητέα ρασαγιλίνη ή φαρμακευτικώς αποδεκτό άλας αυτής.
CY20191100699T 2010-02-03 2019-07-03 Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων CY1121781T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30101910P 2010-02-03 2010-02-03
PCT/IL2011/000126 WO2011095973A1 (en) 2010-02-03 2011-02-03 Extended release formulations of rasagiline and uses thereof

Publications (1)

Publication Number Publication Date
CY1121781T1 true CY1121781T1 (el) 2020-07-31

Family

ID=43896855

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100699T CY1121781T1 (el) 2010-02-03 2019-07-03 Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων

Country Status (25)

Country Link
US (1) US9943489B2 (el)
EP (2) EP2531181B1 (el)
JP (3) JP6045347B2 (el)
KR (1) KR101791715B1 (el)
CN (1) CN102791258B (el)
AU (1) AU2011212068B2 (el)
BR (1) BR112012019374B1 (el)
CA (1) CA2789006C (el)
CL (1) CL2012002175A1 (el)
CY (1) CY1121781T1 (el)
DK (1) DK2531181T3 (el)
ES (1) ES2733133T3 (el)
HU (1) HUE044221T2 (el)
IL (1) IL221274A (el)
LT (1) LT2531181T (el)
MX (1) MX354423B (el)
NZ (1) NZ602111A (el)
PL (1) PL2531181T3 (el)
PT (1) PT2531181T (el)
RS (1) RS58988B1 (el)
RU (2) RU2734632C2 (el)
SG (1) SG183150A1 (el)
TR (1) TR201909277T4 (el)
WO (1) WO2011095973A1 (el)
ZA (1) ZA201206462B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
KR102276896B1 (ko) * 2012-01-12 2021-07-14 파마 투 비 엘티디 파킨슨병의 고정용량 조합 치료법
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
AR092168A1 (es) * 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
IN2013MU01782A (el) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
EP3922242A1 (en) * 2014-09-15 2021-12-15 Orphazyme A/S Arimoclomol formulation
US20180333365A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
KR20210014289A (ko) 2019-07-30 2021-02-09 (주)비씨월드제약 라사길린을 함유하는 서방출성 미립구의 제조방법
WO2022238401A1 (en) * 2021-05-11 2022-11-17 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192808A (en) 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
US5151449A (en) 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
CA2039194C (en) 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5225446A (en) 1990-08-31 1993-07-06 Deprenyl Animal Health, Inc. Use of 1-deprenyl for retention of specific physiological functions
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
WO1992017169A1 (en) 1991-04-04 1992-10-15 The University Of Toronto Innovations Foundation Use of deprenyl to maintain, prevent loss, or recover nerve cell function
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5242950A (en) 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL130528A (en) 1996-12-18 2004-12-15 Teva Pharma Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US5840979A (en) 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
MXPA01010933A (es) 1999-04-29 2002-06-21 Merck Patent Gmbh Inhibidores del sistema de clivaje de la glicina como potenciales antipsicoticos.
EP1411901B1 (en) * 2001-07-04 2010-08-18 Sun Pharma Advanced Research Company Ltd Gastric retention controlled drug delivery system
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
EP2526944B1 (en) * 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
MX2008000084A (es) * 2005-06-29 2008-03-18 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas.
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
JP5726401B2 (ja) * 2005-07-28 2015-06-03 シャイア エルエルシー 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形／組成物
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101486655A (zh) 2008-01-17 2009-07-22 美德（江西）生物科技有限公司 甲磺酸雷沙吉兰晶形及其制备方法
NZ590291A (en) 2008-06-06 2013-11-29 Pharma Two B Ltd Pharmaceutical compositions for treatment of parkinson's disease
EP2285214B1 (en) 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
WO2010007181A2 (en) * 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof

Also Published As

Publication number Publication date
EP2531181B1 (en) 2019-04-10
PL2531181T3 (pl) 2019-09-30
BR112012019374A2 (pt) 2016-05-03
MX354423B (es) 2018-03-02
KR20120130292A (ko) 2012-11-30
IL221274A (en) 2017-05-29
RU2012136723A (ru) 2014-03-10
JP6045347B2 (ja) 2016-12-14
RS58988B1 (sr) 2019-08-30
US20120301542A1 (en) 2012-11-29
WO2011095973A1 (en) 2011-08-11
ZA201206462B (en) 2014-02-26
CA2789006C (en) 2018-11-27
JP2019048855A (ja) 2019-03-28
NZ602111A (en) 2014-10-31
LT2531181T (lt) 2019-07-10
CN102791258A (zh) 2012-11-21
TR201909277T4 (tr) 2019-07-22
DK2531181T3 (da) 2019-07-15
CL2012002175A1 (es) 2013-01-11
US9943489B2 (en) 2018-04-17
HUE044221T2 (hu) 2019-10-28
SG183150A1 (en) 2012-09-27
IL221274A0 (en) 2012-10-31
CA2789006A1 (en) 2011-08-11
EP2531181A1 (en) 2012-12-12
KR101791715B1 (ko) 2017-10-30
JP2013518870A (ja) 2013-05-23
RU2016141314A (ru) 2018-12-14
JP6440662B2 (ja) 2018-12-19
JP6770564B2 (ja) 2020-10-14
EP3517103A1 (en) 2019-07-31
JP2017031189A (ja) 2017-02-09
PT2531181T (pt) 2019-07-17
MX2012009079A (es) 2012-12-17
ES2733133T3 (es) 2019-11-27
AU2011212068B2 (en) 2016-08-18
RU2016141314A3 (el) 2019-12-20
CN102791258B (zh) 2018-05-08
RU2734632C2 (ru) 2020-10-21
AU2011212068A1 (en) 2012-09-20
RU2607595C2 (ru) 2017-01-10
BR112012019374B1 (pt) 2022-01-11

Similar Documents

Publication Publication Date Title
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1120088T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου ως φαρμακo
CY1119886T1 (el) Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους
CY1113108T1 (el) Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
EA200901373A1 (ru) Аминогетероциклические соединения
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
JP2011102304A5 (el)
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
MX2015001917A (es) Composiciones farmaceuticas de memantina.
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης